

Note: This is Online Appendix 1 of Chibabhai V, Bekker A, Black M, et al. Appropriate use of colistin in neonates, infants and children: Interim guidance. S Afr J Infect Dis. 2023;38(1), a555. <https://doi.org/10.4102/sajid.v38i1.555>

Online Appendix 1: Appendix A and B

Appendix A: Practical considerations for administering colistin in neonates, infants and children

Taken from: "Colistin administration in paediatrics; Prof Helena Rabie, Adrie Bekker, Dr Christel du Buisson, Dr Veshni Pillay-Fuentes Lorente and Prof Eric Decloedt; Stellenbosch University Therapeutics Bulletin; November 2021"

Follow the steps below in conjunction with the Table A1:

Step 1: Decide how many vials are needed by assessing the dose prescribed (#1 and #2 in the table)

Step 2: Add 2 mL sterile water for injection into each of the 1 MU colistin (CMS) vial and gently shake each vial until the powder has completely dissolved.

Step 3: Choose the appropriate syringe. If you are using 1-5 vials to dose the patient, draw up the colistin into a 10 mL syringe. If you are using 6 or more vials to dose, draw up all the colistin into a 20 mL syringe (# 3 in the table).

Step 4: If you are using a 10ml syringe draw further sterile water for injection into the 10 mL syringe as per the table below (#4 in the table).

NOTE: If more than one vial is used, add 2 mL sterile water for injection into each vial. Draw up the colistin from all the required vials using the same 10 mL syringe (if 5 vials required) or a 20mL syringe (if > 5 vials required). Use the table below to reconstitute the mixture.

Step 5: Calculate the volume to be injected by dividing the dose in IU by the concentration i.e. the amount of colistin per mL (#5 and #6).

Step 7: Use the port closest to the patient and administer the required dose as a slow bolus injection over 5-10 minutes.

Step 8: Once the slow bolus injection is completed, flush the canula with 2 mL sterile water for injection.

Step 9: Discard all "left over" medication.

Appendix B: Assessing acute kidney injury during administration of colistin

(Adapted from: “Assessing acute kidney injury during administration of nephrotoxic drugs; Prof Helena Rabie, Adrie Bekker, Dr Christel du Buisson, Dr Veshni Pillay-Fuentes Lorente and Prof Eric Decloedt; Stellenbosch University Therapeutics Bulletin; November 2021)

Definition of acute kidney injury (AKI): AKI is a decrease in glomerular filtration rate (GFR), that is manifested by an elevation in serum creatinine (S-Cr) from baseline, and/or a reduction in urine output. AKI is staged according to the Kidney Disease: Improving Global Outcomes (KDIGO) as per Table B1

- Risk factors for colistin associated nephrotoxicity include:
 - Acute-severe illness
 - Nephrotoxin exposure (e.g. NSAIDS, antibiotics, furosemide, contrast, etc)
 - Comorbidities (e.g. sickle cell vaso-occlusive crisis, congenital heart disease)

- Assessing renal function
 - Urine output is VERY important. It reflects perfusion and function, and where AKI is suspected should preferably be monitored and where necessary with a catheter.
 - Review S-Cr but remember the following caveats
 - S-Cr reflects GFR in individuals at steady state with stable kidney function.
 - Affected by several factors.
 - Increases to s-Cr is often a delayed
 - S-Cr does not accurately reflect the GFR in a patient whose kidney function is changing.
 - In neonates initial s-Cr reflect maternal s-Cr

Table B1: KDIGO Classification of renal dysfunction in neonates and children and suggested actions

Stage	Child		Neonate		General Recommendations	Specific Recommendation
	s-Cr	Urine output	s-Cr	Urine output		
1	1.5–1.9 times baseline# in 7 days OR 26.5 µmol/L increase within 48 h	< 0.5 mL/kg/h over 6–12 h	1.5–1.9 Times baseline* in 7 days OR 26.5 µmol/L increase within 48 h	> 0.5 and ≤ 1 mL/kg/h over 24 h	<ul style="list-style-type: none"> • Optimize volume status, and blood pressure • Avoid nephrotoxic agents • Monitor colistin levels if possible 	
2	↑2.0–2.9 times baseline#	< 0.5 mL/kg/h over ≥ 12 h	2.0–2.9 times baseline*	>0.3 and ≤ 0.5	<ul style="list-style-type: none"> • Measure urine output • Repeat s-Cr in 24 hours 	<ul style="list-style-type: none"> • Discuss dosing with Nephrology/Clinical Pharmacology/ID

				mL/kg/h over 24 h		
3	≥ 3.0 times baseline# OR s-Cr ≥ 353.6 µmol/L OR initiation of renal replacement therapy OR decrease in eGFR to < 35 mL/min/1.73 m ²	< 0.3 mL/kg/h ≥ 24 h OR anuria for ≥ 12 h	≥ 3.0 times baseline* OR increase in serum creatinine to ≥ 221 µmol/L OR initiation of renal replacement therapy	≤ 0.3 mL/kg/h over 24 h		<ul style="list-style-type: none"> Actively switch away from nephrotoxic agent if possible Calculate eGFR Adjust dose of all agents where necessary Discuss dosing with Nephrology/Clinical Pharmacology/ID
<ul style="list-style-type: none"> Estimated glomerular filtration rate (eGFR) is calculated using the Bedside Schwartz formula. #Baseline creatine in children = lowest previous value or if none is available, calculate backward using an eGFR of 100–120 mL/min/1.73 m², assuming that previous kidney function was normal. *Baseline creatine in infants > 3 days < 1 month = lowest previous s-Cr <u>AND</u> not more than 95th percentile for gestation and age. GFR (mL/min/1.73 m²) = (0.41 3* Height in cm) / (Creatinine in umol/l * 0.0113) 						
http://nephron.com/bedside_peds_nic.cgi						

Table B2: Estimated glomerular filtration rate (eGFR) normal values for infants > 1 month children

Age	Serum creatinine (µmol/L)	Estimated glomerular filtration rate (eGFR) (mL/min/1.73 m ²)
1 month	18 to 35	48 (28–68)
2 months		58(30–86)
6 months		77(41-103)
9 months		103(49-157)
12 months		115(65-160)
1-10 years	27 to 62	127(89-165)
10 years	44 to 88	85 - 150

Table B3: Creatinine reference ranges for neonates and infants

Gestational age (weeks)	Serum Creatinine ($\mu\text{mol/L}$)			
	Birth	48 hours	7 days	14 days
27-29	77 \pm 12	116 \pm 40	84 \pm 32	72 \pm 32
30-32	65 \pm 4	104 \pm 38	83 \pm 41	69 \pm 32
33-35	73 \pm 6	93 \pm 39	68 \pm 44	55 \pm 36
>36	65 \pm 5	75 \pm 38	50 \pm 36	38 \pm 20